Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.

Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR.

Neoplasia. 2012 Nov;14(11):1005-14.

2.

Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.

Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR.

Cancer Prev Res (Phila). 2011 Feb;4(2):230-7. doi: 10.1158/1940-6207.CAPR-10-0249. Epub 2010 Dec 16.

3.

Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.

Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, Cai Q, Freilino ML, Li C, Johnson DE, Grandis JR.

Carcinogenesis. 2009 Nov;30(11):1848-56. doi: 10.1093/carcin/bgp211. Epub 2009 Sep 16.

Supplemental Content

Loading ...
Support Center